Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170095 | 0.81 | SCN8A (0.50) | CYP1A2SCN8APTGER4GRM2SLC9A1 | |
| SCHEMBL25247023 | 0.80 | SCN8A (0.49) | CYP1A2SCN8APTGER4GRM2SLC9A1 | |
| SCHEMBL5763004 | 0.77 | MPO (0.46) | SLC9A1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL18096451 | 0.76 | PTGER4 (0.47) | CYP1A2SCN8APTGER4GRM2SLC9A1 | |
| SCHEMBL4494497 | 0.74 | ALDH1A1 (0.53) | CYP1A2SCN8APTGER4ALDH1A1CYP2C9 | |
| SCHEMBL1226080 | 0.73 | CNR1 (0.58) | CYP1A2SCN8APTGER4GRM2SLC9A1 | |
| SCHEMBL4485895 | 0.73 | CYP1A2 (0.49) | CYP1A2SCN8APTGER4GRM2ALDH1A1 | |
| SCHEMBL12266572 | 0.71 | HTT (0.43) | CYP1A2ALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL11394780 | 0.71 | SCN8A (0.41) | CYP1A2SCN8APTGER4GRM2SLC9A1 | |
| SCHEMBL4470865 | 0.71 | PTGER4 (0.64) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2012779-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | CYP1A2 805/4885SCN8A 437/4885PTGER4 877/4885 |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | UTS2R, VIPR1, VRK1 | CYP1A2 822/4885SCN8A 410/4885PTGER4 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.